Optimal imaging surveillance interval among durable progression-free survivors after PD-1 blockade for melanoma or non-small cell lung cancer

Patients with non-small cell lung cancer or melanoma with durable progression-free survival (≥ 2 years; dPFSors) after anti-PD1-based treatment are increasingly seen, but data of high quality are lacking in addressing the imaging surveillance intervals. Analysis of individual patient data for PFS extracted from PD-1 blockade clinical trials with a follow-up of at last 5 years examined further progression or death risk among these patients. With a risk threshold of 10%, melanoma dPFSors can be scanned every 6 months during the third year and every 12 months after the third year. The interval for NSCLC would be every 3 months in the third year and every 4 months in years 4 and 5, Higher risk tolerance of 15% and 20% would allow for less frequent scans.